Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $28.33 Average PT from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $28.3344.

A number of equities analysts have recently weighed in on BCAX shares. Wells Fargo & Company boosted their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, Citizens Jmp initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued a “market perform” rating and a $31.00 price target for the company.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara closed an oversubscribed underwritten offering that, including the full exercise of the underwriters’ option, raised roughly $172.5 million in gross proceeds (8,581,250 shares sold plus pre-funded warrants for 2.2M shares). This meaningfully boosts cash to fund development and commercial launch planning. Bicara Announces Closing of Oversubscribed Offering
• Positive Sentiment: Management says proceeds will be used to build medical and commercial infrastructure, fund manufacturing and accelerate filing/commercial plans for ficerafusp alfa — improving the company’s ability to reach regulatory and launch milestones. Bicara Pricing of $150M Offering
• Positive Sentiment: Discussion and coverage of clinical data for ficerafusp alfa — including work on less-frequent dosing in first-line HPV‑negative head & neck cancer — may lift investor confidence in the program’s commercial potential if data readouts remain favorable. Seeking Alpha: Clinical Data & Less-Frequent Dosing
• Positive Sentiment: A small institutional stake (Bleakley Financial Group) was reported as a new purchase, indicating some institutional buying interest. Bleakley Financial Group Investment
• Neutral Sentiment: Various coverage (including an AAII piece) explained the stock’s intraday moves and earlier rally; that context helps understand momentum but doesn’t change fundamentals. AAII: Why BCAX Was Up
• Neutral Sentiment: Published short-interest figures in the feeds show zero/invalid values and are not reliable for gauging near-term short pressure (reports appear to contain errors).
• Negative Sentiment: The equity raise is dilutive: the new shares plus pre-funded warrants will increase share count and can pressure the stock price until the company demonstrates clinical/regulatory progress that justifies the higher valuation. See media coverage summarizing the offering and dilution risks. Quiver: Pricing of Public Offering
• Negative Sentiment: Recent public records summarized in market write-ups show notable insider selling over recent months, which some investors view negatively even if proceeds were planned. Quiver: Insider Activity & Offering Context

Insider Buying and Selling

In other news, COO Ryan Cohlhepp sold 3,828 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total transaction of $69,286.80. Following the completion of the sale, the chief operating officer directly owned 210,164 shares of the company’s stock, valued at $3,803,968.40. The trade was a 1.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Ivan Hyep sold 1,882 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $18.15, for a total value of $34,158.30. Following the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,638,193.25. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 18,359 shares of company stock valued at $339,630. 15.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCAX. Deutsche Bank AG increased its stake in Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after acquiring an additional 1,171 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the period. Mariner LLC increased its position in Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after purchasing an additional 1,902 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Bicara Therapeutics by 13.2% in the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after buying an additional 1,962 shares during the period.

Bicara Therapeutics Trading Down 4.1%

Bicara Therapeutics stock opened at $16.80 on Tuesday. The stock has a 50-day moving average price of $16.41 and a 200 day moving average price of $15.46. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $19.71. The stock has a market cap of $920.30 million, a PE ratio of -7.50 and a beta of -0.79.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.